Hisun licenses Xuanjing's siRNA platform for cardiovascular and metabolic targets
Chinese drugmaker Hisun Pharmaceutical has licensed Xuanjing Bio's liver-targeting GalNAc delivery platform and the preclinical siRNA candidate RGN6669 for cardiovascular, metabolic and respiratory disease targets.
What happened
Zhejiang Hisun Pharmaceutical signed a small-nucleic-acid licensing agreement with Suzhou Xuanjing Bio and its Beijing subsidiary on 13 November. Xuanjing grants rights to its liver-targeting GalNAc delivery platform against specified targets in cardiovascular, metabolic and respiratory disease, and licenses RGN6669, an early preclinical liver-targeted siRNA candidate.
The numbers
- Signing: 13 November.
- Assets: GalNAc delivery platform and RGN6669.
- Therapeutic areas: cardiovascular, metabolic and respiratory.
- Financial terms: not disclosed.
Why it matters
This is a platform deal, not a single-asset purchase. Hisun gets a modality it can apply across targets without building early discovery, and Xuanjing gets a licensee that can develop and commercialise in China's largest chronic-disease markets. siRNA is moving from oncology hype into cardiovascular and metabolic disease, where patient numbers and payer pressure are both large.
The counter-argument is that RGN6669 is preclinical, so the deal is a bet on delivery rather than on data. Undisclosed terms make it impossible to judge the split of risk. The strategic point stands: Chinese pharma is buying platform access, which lets biotechs monetise repeatedly rather than once.
What to watch
- IND filing and first clinical data for RGN6669.
- Any disclosure of upfront and milestone terms.
- Further Xuanjing platform licences in other therapeutic areas.
Original source: NetEase · 13 Nov 2026
